Biomerica, Inc. (BMRA): Price and Financial Metrics


Biomerica, Inc. (BMRA): $6.48

0.10 (+1.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BMRA Stock Summary

  • BMRA has a market capitalization of $75,156,968 -- more than approximately just 13.99% of US stocks.
  • BMRA's went public 4.49 years ago, making it older than merely 15.75% of listed US stocks we're tracking.
  • Over the past twelve months, BMRA has reported earnings growth of 83.5%, putting it ahead of 86.22% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biomerica Inc are KOPN, ASTC, AEIS, UTSI, and OPTT.
  • BMRA's SEC filings can be seen here. And to visit Biomerica Inc's official web site, go to www.biomerica.com.

BMRA Stock Price Chart Interactive Chart >

Price chart for BMRA

BMRA Price/Volume Stats

Current price $6.48 52-week high $23.39
Prev. close $6.38 52-week low $2.05
Day low $6.36 Volume 74,600
Day high $6.61 Avg. volume 615,992
50-day MA $6.29 Dividend yield N/A
200-day MA $6.98 Market Cap 76.33M

Biomerica, Inc. (BMRA) Company Bio


Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.


BMRA Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRA Latest Social Stream


Loading social stream, please wait...

View Full BMRA Social Stream

Latest BMRA News From Around the Web

Below are the latest news stories about Biomerica Inc that investors may wish to consider to help them evaluate BMRA as an investment opportunity.

We Think Biomerica (NASDAQ:BMRA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Biomerica ( NASDAQ:BMRA...

Yahoo | February 17, 2021

Biomerica’s Fast 15-Minute Simple to Use Covid-19 Antigen Rapid Test Receives CE Mark

* Biomerica receives first orders and plans to ship tests in coming weeks   * Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR testsIRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it has received CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 infection. The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. The Company will now begin marketing this product broadly in Europe and other regions outside of the US.Biomerica’s new COVID-19 Antigen Rapid Test is highly...

Yahoo | January 12, 2021

Imagine Holding Biomerica (NASDAQ:BMRA) Shares While The Price Zoomed 302% Higher

Some Biomerica, Inc. ( NASDAQ:BMRA ) shareholders are probably rather concerned to see the share price fall 32% over...

Yahoo | January 3, 2021

BMRA: InFoods Clinical Trial Advances, Further Step Towards Potential FDA Clearance

By M. Marin NASDAQ:BMRA READ THE FULL BMRA RESEARCH REPORT Last week, Biomerica (NASDAQ:BMRA) announced that it is nearing completion of patient enrollment in the InFoods® IBS endpoint clinical trial. As a diagnostic-guided therapy (not a drug), InFoods does not have the side effects drugs often have and can be used alone and/or as part of a drug therapy program. Patient enrollments are expected

Yahoo | December 16, 2020

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

* Patient enrollment completion anticipated by the end of April 2021 * InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatment * Therapy seeks to identify patient-specific foods that trigger IBS symptoms and suffering * Approximately 45 million Americans suffer from IBS1IRVINE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it is nearing completion of patient enrollment in the endpoint clinical trial for its InFoods® Irritable Bowel Syndrome (“IBS”) diagnostic-guided therapy (“DGT”). This double-blinded, randomized, controlled clinical trial is validating the Biomerica InFoods® IBS test to manage the debilitating pain and suffering of patients diagno...

Yahoo | December 9, 2020

Read More 'BMRA' Stories Here

BMRA Price Returns

1-mo -10.99%
3-mo -3.86%
6-mo -12.08%
1-year 137.36%
3-year 41.48%
5-year 472.94%
YTD 30.12%
2020 64.68%
2019 77.88%
2018 -54.55%
2017 62.61%
2016 78.29%

Continue Researching BMRA

Here are a few links from around the web to help you further your research on Biomerica Inc's stock as an investment opportunity:

Biomerica Inc (BMRA) Stock Price | Nasdaq
Biomerica Inc (BMRA) Stock Quote, History and News - Yahoo Finance
Biomerica Inc (BMRA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8255 seconds.